Clinical Commander

Back to dossier
pulm.pleural-effusion.core.v1PRODUCTION
pulm.pleural-effusion.core.v1

Pleural Effusion

pulmonologyacutesubacutechronicadult
Hard-required inputs
0 / 8
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Confirm pleural effusion (vs consolidation, atelectasis, elevated hemidiaphragm, pleural thickening) on CXR/US and determine acuity + bilaterality (bilateral → transudate-leaning)

Inputs
1
Actions
0
Advance rule
Set
Advance when

Effusion confirmed by imaging

Patient inputs (21)

Etiology pretest probability (cancer, parapneumonic) shifts with age (BTS 2023)

Hypoxia for thoracentesis urgency (BTS 2023)

Tachypnea + work-of-breathing severity (BTS 2023)

Pleural infection screen (BTS 2023)

Septic shock screen in pleural infection (BTS 2023)

Transudative substrate identification + drives Light's albumin-gradient correction

Pre-procedural bleeding risk for thoracentesis (BTS 2023)

Initial confirmation + lateral decubitus for layering (BTS 2023)

ADA >40 U/L → LR+ ~9 for TB pleuritis (Aggarwal 2019 PMID 30913213)

Cytology pooled sensitivity 58% single sample; repeat → ~80% (PMID 35110369)

Loculation, malignant features (pleural thickening, nodularity, mediastinal pleural involvement) (BTS 2023; ATS/STS 2018)

Parapneumonic vs hemothorax differential (BTS 2023)

Diuretics concentrate transudate protein/LDH → pseudo-exudate; triggers albumin-gradient / NT-proBNP correction (Bielsa 2007 PMID 17875051)

Light's criterion denominator — pleural/serum protein >0.5 (Light 1972 PMID 4642731)

Light's criterion denominator — pleural/serum LDH >0.6 or pleural LDH >2/3 ULN (Light 1972 PMID 4642731)

Serum-pleural albumin gradient >1.2 g/dL reclassifies diuretic-treated HF pseudo-exudate (Bielsa 2007 PMID 17875051)

pH <7.20 → complicated parapneumonic requiring drainage (BTS 2023; collect anaerobically in heparinised ABG syringe)

NT-proBNP for cardiac effusion misclassified by Light (LR+ 15.2; PMID 20511623)

Platelets >=50 generally accepted for thoracentesis (BTS 2023)

INR <2 generally accepted for thoracentesis (BTS 2023)

Bedside characterization (loculation, septations) + always US-guided thoracentesis (BTS 2023)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (9)

9 need judgement
  • informationallife_threateningsepsis_from_pleural_infection
    Pleural infection with septic shock (vasopressor) or organ dysfunction
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateninghemothorax_massive
    Initial chest tube drainage >1500 mL OR continued >200 mL/h × 4 h OR hemodynamic instability
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereempyema_or_complex_parapneumonic
    Frank pus on aspirate OR pleural fluid pH <7.20 OR positive Gram stain/culture OR loculation on US
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverepleural_infection_high_rapid_risk
    RAPID score high-risk band (5-7 points) — 3-month mortality 29.3% (PILOT Corcoran 2020 PMID 32675200)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveremassive_effusion_with_respiratory_failure
    Large effusion (≥hemithorax) with hypoxic respiratory failure or mediastinal shift
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverehepatic_hydrothorax_refractory
    Cirrhotic transudative effusion (usually right-sided) refractory to diuretics + Na restriction
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatemalignant_pleural_effusion_recurrent
    Recurrent symptomatic MPE despite repeated thoracentesis (cytology pooled sensitivity 58% single sample — repeat if negative; PMID 35110369)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatetrapped_lung
    Incomplete lung re-expansion after drainage on imaging (visceral pleural restriction)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatetb_pleurisy
    Pleural ADA >40 U/L (LR+ ~9; Aggarwal 2019 PMID 30913213), lymphocyte-predominant exudate, or AFB / TB-PCR positive
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSoptionalDrives severity classification
Loading…

Recommended regimen

BTS 2023 + ATS/STS/STR 2018 — drainage strategy + substrate-directed therapy
axis: pleural_effusion_drainage_and_substratestep transudate_treat_substrate - Transudate — treat underlying disease, drain only if symptomatic
Selected step "Transudate — treat underlying disease, drain only if symptomatic" — Light's criteria all negative (or serum-pleural albumin gradient >1.2 g/dL / NT-proBNP reclassifies a diuretic-treated pseudo-exudate); HF / cirrhosis / nephrotic / hypoalbuminemia / urinothorax
  • furosemide
    first line
    loop_diuretic
    40 mg IV/PO daily-BID (titrate), or 20 mg IV bolus + 5-10 mg/h infusion • IV/PO • daily-BID titrated to response
    triggers: HF_or_volume_overload
    Treat HF cause; UOP target 1-2 L/d net negative (BTS 2023; cardio.acute-hf.core.v1 GDMT)
    rxcui 4603
  • spironolactone
    add on
    MR_antagonist
    100 mg PO daily (cirrhosis, 100:40 ratio with furosemide); 25-50 mg PO daily (HF) • PO • daily
    triggers: cirrhosis, HF_with_K_low
    Cirrhotic hepatic hydrothorax + HF — synergistic (AASLD 2021; gi.cirrhosis.core.v1)
    rxcui 9997
  • albumin human 25%
    add on
    colloid
    25 g IV after large-volume thoracentesis (>1.5 L) • IV • single dose post-procedure
    triggers: hepatic_hydrothorax_LVT
    Reduces post-paracentesis circulatory dysfunction; extrapolated to hepatic hydrothorax (AASLD 2021)
    rxcui 828529

outpatient playbook — drug actions (3)

  1. 1. home IPC drainage
    ≤1 L PRN, taper as drainage decreases • IPC • home schedule per AMPLE
    trigger: Recurrent MPE on IPC
    Spontaneous pleurodesis ~46% by 70 d (AMPLE PMID 29164255)
  2. 2. continue diuresis
    Furosemide + spironolactone titrated • PO • daily
    trigger: HF / cirrhotic substrate
    Substrate control (BTS 2023)
  3. 3. cephalexin if IPC site cellulitis
    500 mg PO QID × 5 d • PO • q6h × 5 d
    trigger: IPC site erythema/cellulitis
    Treat without removing catheter unless deep infection (BTS 2023)

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Dyspnea, pleuritic chest pain, dull cough (BTS 2023 Roberts); Pleural effusion on CXR / lung ultrasound / CT (BTS 2023); Diminished breath sounds, dullness on percussion, reduced tactile fremitus (BTS 2023).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Pleural Effusion** (pulm.pleural-effusion.core.v1).
Phenotype framing: Bayesian fork: Light's exudate (any 1 of 3 criteria) → parapneumonic/empyema, malignant, TB, PE, autoimmune, chylothorax, post-CABG; Light's transudate → HF, cirrhosis (hepatic hydrothorax), nephrotic, hypoalbuminemia, urinothorax. Apply albumin-gradient/NT-proBNP correction for diuretic-treated HF; remember PE can be exudate OR transudate and post-empyema can leave trapped lung
Scope: Confirm pleural effusion (vs consolidation, atelectasis, elevated hemidiaphragm, pleural thickening) on CXR/US and determine acuity + bilaterality (bilateral → transudate-leaning)

No severity triggers fired against current inputs.

Plan

Regimen axis: **BTS 2023 + ATS/STS/STR 2018 — drainage strategy + substrate-directed therapy** — step "Transudate — treat underlying disease, drain only if symptomatic".
1. furosemide 40 mg IV/PO daily-BID (titrate), or 20 mg IV bolus + 5-10 mg/h infusion IV/PO daily-BID titrated to response (loop_diuretic, first line) — Treat HF cause; UOP target 1-2 L/d net negative (BTS 2023; cardio.acute-hf.core.v1 GDMT)
2. spironolactone 100 mg PO daily (cirrhosis, 100:40 ratio with furosemide); 25-50 mg PO daily (HF) PO daily (MR_antagonist, add on) — Cirrhotic hepatic hydrothorax + HF — synergistic (AASLD 2021; gi.cirrhosis.core.v1)
3. albumin human 25% 25 g IV after large-volume thoracentesis (>1.5 L) IV single dose post-procedure (colloid, add on) — Reduces post-paracentesis circulatory dysfunction; extrapolated to hepatic hydrothorax (AASLD 2021)

Setting playbook (outpatient) — Manage chronic / recurrent effusion (MPE on IPC, hepatic hydrothorax, HF-related) and avoid hospitalisation when possible
4. home IPC drainage ≤1 L PRN, taper as drainage decreases IPC home schedule per AMPLE — Recurrent MPE on IPC (Spontaneous pleurodesis ~46% by 70 d (AMPLE PMID 29164255))
5. continue diuresis Furosemide + spironolactone titrated PO daily — HF / cirrhotic substrate (Substrate control (BTS 2023))
6. cephalexin if IPC site cellulitis 500 mg PO QID × 5 d PO q6h × 5 d — IPC site erythema/cellulitis (Treat without removing catheter unless deep infection (BTS 2023))

Non-pharmacologic actions:
- IPC patient/caregiver training — sterile technique, recognising infection (AMPLE PMID 29164255)
- Home drainage schedule per AMPLE pathway (PMID 29164255)
- Oncology follow-up (ATS/STS 2018)
- Substrate-disease optimisation visits (BTS 2023)

AVOID / contraindication checks:
- Thoracentesis platelet >=50 INR <2 (BTS 2023)
- Intrapleural_tPA_avoid_if_active_haemorrhage_or_recent_thoracic_surgery (MIST2 Rahman NEJM 2011)
- Hepatic_hydrothorax_avoid_conventional_chest_tube_high_mortality (AASLD 2021)
- Talc use graded only avoid ungraded ARDS risk (TAPPS Bhatnagar 2020)
- IPC avoid in active pleural infection unless drainage (BTS 2023)
- Large_volume_thoracentesis_cap_1.5L_re_expansion_oedema (BTS 2023)
- INH pyridoxine supplementation (WHO TB 2022)

Monitoring

Regimen monitoring:
- serial drain output (BTS 2023)
- daily CXR after tube placement (BTS 2023)
- fever curve in pleural infection (BTS 2023)
- CRP trend in empyema (BTS 2023)
- pleural-space bleeding watch during tPA/DNase course (MIST2)
- IPC site inspection each drainage (BTS 2023)
- oncology imaging per disease protocol (ATS/STS 2018)

Setting (outpatient) monitoring:
- Home drain volume diary (AMPLE PMID 29164255)
- IPC site inspection at each drainage (BTS 2023)
- Phone follow-up at 2 weeks then monthly (BTS 2023)

Follow-up plan: Outpatient IPC management (3×/week drainage, taper for spontaneous pleurodesis ~46% by 70 d on AMPLE), oncology re-imaging, HF/cirrhosis substrate optimisation, repeat thoracentesis if recurrent, asbestos counselling + smoking cessation
- Close-out criterion: Drainage and substrate plan in place; clinic follow-up scheduled

Monitoring phase: Drain output, daily post-tube CXR, repeat US, fever/CRP curve in pleural infection, IPC site care, reaccumulation rate

Disposition

Current setting: outpatient — Manage chronic / recurrent effusion (MPE on IPC, hepatic hydrothorax, HF-related) and avoid hospitalisation when possible

Disposition criteria:
- Continue IPC until spontaneous pleurodesis or end-of-life care plan (AMPLE PMID 29164255)
- Remove IPC after spontaneous pleurodesis confirmed (AMPLE PMID 29164255)

Escalation triggers (move to higher acuity):
- Pleural-space infection on IPC → admit, broaden antibiotics, consider removal (BTS 2023)
- Drain failure / blockage → admission for catheter exchange (BTS 2023)
- New respiratory failure → ED (BTS 2023)

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Pleural infection with septic shock (vasopressor) or organ dysfunction
- [LIFE_THREATENING] Initial chest tube drainage >1500 mL OR continued >200 mL/h × 4 h OR hemodynamic instability
- [SEVERE] Frank pus on aspirate OR pleural fluid pH <7.20 OR positive Gram stain/culture OR loculation on US

Citations

- BTS 2023 Guideline for Pleural Disease (Roberts) + ATS/STS/STR 2018 MPE Management (Feller-Kopman) [PMID:4642731](https://pubmed.ncbi.nlm.nih.gov/4642731/)
- Cited evidence (PMID 21830966) [PMID:21830966](https://pubmed.ncbi.nlm.nih.gov/21830966/)
- Cited evidence (PMID 15745977) [PMID:15745977](https://pubmed.ncbi.nlm.nih.gov/15745977/)
- Cited evidence (PMID 32675200) [PMID:32675200](https://pubmed.ncbi.nlm.nih.gov/32675200/)
- Cited evidence (PMID 29164255) [PMID:29164255](https://pubmed.ncbi.nlm.nih.gov/29164255/)

Last reconciled with current guidelines: 2026-05-16.
References